argenx (ARGX.BR) Osake Kurssi
argenx Kurssi
Liikevaihto on kasvanut 74,7 % vuodessa viimeisten 14 vuoden aikana 3,60 Mrd. USD:een. argenxn nettomarginaali on nyt 31,1 %, noussut −37,9 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 981,64 USD, eli yli nykyhintaa 13,9 %. 25 analyytikosta 22 suosittaa ostoa — kokonaiskonsensus on Osta.
argenx osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
argenx liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset argenx -osakkeesta
argenx SE is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of argenx SE in the market include companies such as Genmab A/S, Alexion Pharmaceuticals Inc., and MorphoSys AG.
The business model of argenx SE revolves around developing and commercializing innovative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. With an emphasis on the discovery and development of uniquely differentiated antibody-based therapies, argenx combines its expertise in immunology and antibody engineering to target specific disease indications. The company focuses on both in-house discovery programs as well as collaborations with global partners to advance its pipeline of potential breakthrough treatments. By leveraging its expertise and strategic partnerships, argenx aims to bring transformative therapies to market and improve the lives of patients suffering from severe diseases.
argenx SE is a renowned biotechnology company with a rich history and significant accomplishments. Founded in 2008, argenx focuses on the discovery and development of innovative antibody-based therapeutics to benefit patients with severe autoimmune diseases and cancer. The company utilizes its unique Simple Antibody platform to engineer and manufacture differentiated therapeutic antibodies. Throughout its history, argenx has achieved numerous milestones, including successful clinical trials and collaborations with leading pharmaceutical companies. With its dedicated team of scientists and commitment to scientific excellence, argenx SE continues to make groundbreaking contributions in the field of biotechnology.
argenx SE has achieved several significant milestones in its history. It successfully completed a Phase 3 clinical trial for its product candidate efgartigimod, which demonstrated positive results in the treatment of generalized myasthenia gravis. The company also obtained breakthrough therapy designation from the U.S. FDA for efgartigimod in the same indication. Furthermore, argenx SE entered into strategic collaborations with multiple pharmaceutical companies to develop and commercialize its innovative antibody-based therapies. These partnerships include agreements with Janssen for cusatuzumab, Cilag GmbH International for ARGX-112, and Leo Pharma for ARGX-112. Overall, argenx SE has made significant strides in its quest to develop transformative medicines for patients.
argenx SE is primarily present in various countries and regions around the world. The company has a global presence, with key operations and offices located in Europe, particularly in Belgium and the Netherlands. Additionally, argenx SE has expanded its footprint to North America, with offices and clinical development activities in the United States. Through its international presence, argenx SE aims to capitalize on the opportunities available in different markets and establish a strong presence in the biotechnology and pharmaceutical industry.
argenx SE is a biotechnology company that represents a strong set of values and corporate philosophy. With a focus on patients, collaboration, and innovation, argenx aims to transform the lives of people suffering from severe autoimmune diseases and cancer. The company is committed to developing breakthrough therapies based on its unique antibody engineering platform. By combining cutting-edge science, strategic partnerships, and a patient-centered approach, argenx strives to create meaningful impact in the healthcare industry. With its dedication to excellence and a relentless pursuit of scientific advancements, argenx SE has become a leading player in the biotech sector.
Analyytikot asettavat tällä hetkellä argenx-osakkeelle keskimääräisen tavoitehinnan 985,32 USD (mediaani: 981,64 USD), mikä merkitsee +12,1 % viimeisimpään hintaan verrattuna. Konsensus perustuu 25 analyytikkoarvioon.
25 analyytikkoa arvioi tällä hetkellä argenx-osaketta: 22 suosittaa ostoa, 3 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat argenx-yhtiöltä 6,50 Mrd. USD liikevaihtoa ja 30,52 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla argenx-osake noteerataan hintaan 769,75 EUR (862,20 USD).
argenx-osake (ARGX.BR) on listattuna 8 pörssissä, muun muassa: London (0QW0.L), Frankfurt (1AE.F), München (1AE.MU), Düsseldorf (1AE.DU), Wien (ARGX.VI).
argenx SE is a biopharmaceutical company involved in the development and commercialization of therapeutic antibodies. The company operates in various areas, including antibody discovery, data collection, clinical development, manufacturing, and drug marketing. Their research focuses on autoimmune diseases, inflammatory diseases, and cancer. arGEN-X has successfully completed numerous clinical trials and has a wide range of products in various stages of development. The company also seeks partnerships with other biopharmaceutical companies to accelerate the development of new products. Their goal is to discover, develop, and market novel antibodies to treat seriously ill patients.
odotettu liikevaihto argenx on 6,50 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto argenx on 2,02 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
argenx:n hinta-voitto-suhde (P/E) on tällä hetkellä 28,25. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan argenx-osakkeen arvostusta.
argenx:n hinta-myynti-suhde (P/S) on tällä hetkellä 8,79. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii argenx-osakkeen arvostuskennuslukuna.
argenx:n Eulpool-laatuscore on 7/10.
argenx:n ISIN on NL0010832176. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
argenx:n WKN on A11602. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
argenx:n ticker on ARGX.BR. Tämä pörssinoteeraus käytetään argenx-osakkeiden kauppaan pörssissä.
argenx osake
argenx vertaisryhmä
argenx Ticker
argenx FIGI
Kaikki tunnusluvut ja syvällinen analyysi argenx:sta
Meidän osakeanalyysimme argenx-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut argenx:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: